Progress in the study of Her2-targeted cancer therapeutic antibodies.
- Author:
Liang CHANG
;
Chen-hui LI
;
Jian GAO
- Publication Type:Journal Article
- MeSH:
Antibodies, Bispecific;
therapeutic use;
Antibodies, Monoclonal;
therapeutic use;
Humans;
Immunoconjugates;
therapeutic use;
Neoplasms;
drug therapy;
Receptor, ErbB-2;
immunology
- From:
Acta Pharmaceutica Sinica
2015;50(5):516-520
- CountryChina
- Language:Chinese
-
Abstract:
Tumor surface antigen human epidermal growth factor receptor 2 (Her2) is a type I receptor tyrosine kinase, which belongs to human epidermal growth factor receptor family. Her2-overexpression is associated with tumorigenesis and metastasis. Due to significant clinical effects, Her2-targeted cancer therapy especially therapeutic antibody has become the hot spot in the field of cancer treatment. Anti-Her2 antibody drugs include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and emerging "two in one" antibody. Based on structure and function of Her2, this review focuses on recent advances in active mechanisms and clinical researches of these antibodies.
